<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00418015</url>
  </required_header>
  <id_info>
    <org_study_id>0524-025</org_study_id>
    <nct_id>NCT00418015</nct_id>
  </id_info>
  <brief_title>Mu-Opioid Receptor Genetic Polymorphism and Intrathecal Analgesia</brief_title>
  <official_title>Mu-Opioid Receptor Genetic Polymorphism and the Duration of Intrathecal Fentanyl Labor Analgesia. Mu-Opioid Receptor Genetic Polymorphism and the Efficacy of Postoperative Intrathecal Morphine Analgesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pharmacogenetics has allowed clinicians to identify associations between an individual's
      genetic profile and his/her response to drugs. The A118G (c.188A&gt;G)is a single nucleotide
      polymorphism (SNP) of the mu-opioid receptor (OPRM1). The mutated protein, N40D, appears to
      increase the binding affinity and potency of beta-endorphin approximately 3-fold. Individuals
      carrying the variant receptor gene (A118G) may show differences in some of the functions
      mediated by beta-endorphin action at the altered OPRM1. Combined spinal-epidural (CSE)
      analgesia is a commonly utilized technique for labor analgesia. Analgesia is initiated with
      the intrathecal administration of a lipid-soluble opioid (e.g. fentanyl), sometimes combined
      with a local anesthetic. The mean (± SD) duration of analgesia after intrathecal fentanyl 25
      microgram was 89 ± 43 min. The ED50 of intrathecal fentanyl for labor analgesia varies
      between 14 microgram to 18.2 microgram. The wide variability in the duration of analgesia, as
      was well the differences in ED50 may result from differences known to affect labor pain
      (e.g., ethnicity, parity, stage of labor). Another possible explanation for the differences
      in opioid requirements and duration, as well as incidence of side effects such as itching and
      nausea/vomiting, is that opioid responsiveness is determined by genetic variability of the
      µ-opioid receptor. The ED50 for intrathecal fentanyl labor analgesia was significantly lower
      for parturients carrying the A118G variant of the mu-opioid receptor, compared to parturients
      with the A118 wild type receptor. The purpose of this study is to determine whether
      polymorphism at nucleotide 118 of OPRM1 influences the duration of intrathecal opioid
      (fentanyl) labor analgesia, and intrathecal opioid (morphine) postoperative analgesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study 1 (intrathecal fentanyl): The primary outcome variable is duration of intrathecal
      fentanyl analgesia. A two-sided log rank test with an overall sample size of 152 subjects
      (wild type OPRM1 = 106, variant OPRM1 = 46) achieves 80% power at α = 0.05 to detect a
      difference of 0.2 between 0.5 and 0.3 (the proportion of subjects with continuing intrathecal
      fentanyl analgesia after 70 min). This assumes that 70% of subjects will have the wild-type
      MUOR1 phenotype, and 30% the variant phenotype. To account for anticipated subject dropout,
      175 subjects will be enrolled in the study.

      Study 2 (intrathecal morphine): The primary outcome variable is amount of rescue analgesia
      (morphine equivalents) necessary for 24 h after the intrathecal morphine injection. An
      overall sample size of 71 subjects (wild type OPRM1 = 50, variant OPRM1 = 21) achieves 81%
      power to detect a difference of 15 mg morphine equivalents between the null hypothesis that
      both group means are 40 mg morphine equivalents and the alternative hypothesis that the mean
      of one group is 25 mg morphine equivalents. The estimated group standard deviations are 20 mg
      morphine equivalents with alpha = 0.05 using a two-side Mann-Whitney test assuming that the
      actual distribution is uniform. This assumes that 70% of subjects will have the wild-type
      OPRM1 phenotype, and 30% the variant phenotype. To account for anticipated subject dropout,
      90 subjects will be enrolled in the study.

      Protocol specific methods:

      Study 1: Eligible parturients admitted to the Labor and Delivery Unit of Prentice Women's
      Hospital will be approached for study participation immediately after the routine
      preanesthetic evaluation. This occurs shortly after admission to the Labor and Delivery Unit.
      Women who agree to participate will give written, informed consent at this time.

      Venous blood will be obtained for genetic analysis of the 118 position of the µ-opioid
      receptor gene shortly after the subject consents to study participation, either through an
      intravenous catheter placed for routine intravenous access for labor and delivery, or through
      a fresh venipuncture. A total of 10 mL blood will be collected into two 5 mL EDTA tubes. The
      tubes will be batched, coded and stored in a 40C refrigerator until they will be send
      (1x/month) to the laboratory of Dr. J. L. Blouin, care of Dr. Landau, at the Hopitaux
      Universitaires de Geneve. Genetic analysis will be performed as described below. When the
      subject first requests analgesia, her cervix will be examined (this is routine procedure
      prior to initiating analgesia). If the cervix is dilated between 2 and 5 cm, the parturient
      will be included in the study. Visual analogue score (VAS) for pain (100 mm line where 0 mm =
      no pain and 100 mm = worst possible pain) will be determined immediately before initiation of
      analgesia. Combined spinal-epidural analgesia will be initiated in the sitting position per
      routine with intrathecal fentanyl 25 microgram. An epidural catheter will be sited. No drug
      will be injected through the epidural catheter until the parturient requests analgesia again.
      The parturient will be placed in the lateral position after the epidural catheter is secured.
      A VAS will be determined 10 min after the intrathecal injection.

      The primary outcome variable is duration of intrathecal fentanyl analgesia.At the time the
      parturient requests additional analgesia, the cervix will be examined. A VAS will be
      determined. In addition, the parturient will be asked about the presence of pruritus since
      the initiation of analgesia (none, mild, moderate, severe), nausea (none, mild, moderate or
      severe), and vomiting (yes, no). An epidural test dose will be administered (lidocaine 1.5%
      with epinephrine 1:200,000). Assuming a negative test dose, bupivacaine 0.125% will be
      injected incrementally to a T10 sensory level. Epidural analgesia will be maintained with
      patient controlled epidural analgesia (PCEA) (bupivacaine 0.0625% with fentanyl 1.95 micro
      grams/mL: background infusion 15 mL/h, PCEA bolus 5 mL, lockout 10 min, maximum 30 mL/h) as
      per routine.

      The study ends after the parturient delivers and the epidural infusion is discontinued. At
      this time the subject will be asked about her satisfaction with labor analgesia (100 mm
      scale, 0 mm = not satisfied at all, 100 mm = very satisfied).

      The following data will be collected: maternal age, height, weight, race (self-described),
      cervical dilation at initiation of analgesia, time and cervical dilation at 2nd request for
      analgesia, maximum oxytocin dose, time to complete cervical dilation (10 cm), time to
      delivery, mode of delivery, neonatal weight, Apgar scores and umbilical blood gas values
      (obtained as part of routine care), total dose of epidural bupivacaine and other local
      anesthetics, total dose of epidural fentanyl, number of PCEA boluses and number of manual
      boluses (by the anesthesiologist).

      Cases will be excluded from data analysis if CSE analgesia is not performed, if there is no
      analgesia (VAS &gt; 10 mm) 10 minutes after the intrathecal injection (failure of CSE
      technique), if cervical dilation is 8 cm within 60 minutes of intrathecal injection, or if
      the patient has a cesarean delivery. These cases will be reported.

      Study 2: Eligible women admitted to the Labor and Delivery Unit of Prentice Women's Hospital
      for planned Cesarean delivery will be approached for study participation immediately after
      the routine preanesthetic evaluation. This occurs shortly after admission to the Labor and
      Delivery Unit. Women who agree to participate will give written, informed consent at this
      time.

      Venous blood will be obtained for genetic analysis of the 118 position of the µ-opioid
      receptor gene shortly after the subject consents to study participation, either through an
      intravenous catheter placed for routine intravenous access for labor and delivery, or through
      a fresh venipuncture. A total of 10 mL blood will be collected into two 5 mL EDTA tubes. The
      tubes will be batched, coded and stored in a 4oC refrigerator until they are sent
      (1time/month) to the laboratory of Dr. J. L. Blouin, care of Dr. Landau, at the Hospitaux
      Universitaires de Geneve. Genetic analysis will be performed as described below Routine
      aspiration prophylaxis will be administered (intravenous ranitidine and metoclopramide, and
      oral antacid). Spinal anesthesia will be initiated in the sitting position in the routine
      manner with bupivacaine 12 mg (1.6 mL 0.75% hyperbaric bupivacaine), fentanyl 15 µg, and
      morphine 150 micrograms. Subjects will be placed in the supine left uterine displacement
      position immediately after the intrathecal injection. The level of cephalad sensory blockade
      will be determined 30 min after the intrathecal injection using von Frye hairs. Subjects with
      a sensory level below T6, or those that require intraoperative systemic opioid
      supplementation, will be excluded from further study participation.

      In the PACU and for 24 hours after surgery, patients will receive ibuprofen 600 mg po q6h as
      per standard protocol. Patients may request rescue analgesia if they are experiencing
      discomfort. Rescue medication will consist of hydrocodone 10 mg plus acetaminophen 325 mg per
      os. An additional dose of hydrocodone 10 mg plus acetaminophen 325 mg will be provided after
      1 hour if the pain is not relieved. These are routine oral analgesic medications for
      postoperative Cesarean delivery analgesia. Standard orders will be written for monitoring
      sedation and respiratory rate, and treatment of side effects (nausea, vomiting, pruritus and
      respiratory depression).

      The primary outcome variable is amount of rescue morphine equivalent analgesia required for
      the 24 hours after the intrathecal morphine injection.18 The time of first rescue analgesia
      request will be noted, and the VAS will be determined at the time of request for rescue
      analgesia. In addition, the parturient will be asked to provide a VAS for pain at 4, 8, 12,
      18, and 24 hours after the intrathecal injection. The presence of pruritus (none, mild,
      moderate, severe), nausea (none, mild, moderate or severe), and vomiting (yes, no) will be
      determined at 4 and 24 h after the intrathecal injection.

      The study ends 24 h after the intrathecal injection. At this time the subject will be asked
      about her satisfaction with postoperative analgesia (100 mm scale, 0 mm = not satisfied at
      all, 100 mm = very satisfied). Further analgesia will not be dictated by study protocol.

      The following data will be collected: maternal age, height, weight, race (self-described),
      requirement for supplemental intraoperative sedation, neonatal weight, intra- or
      postoperative treatment for pruritus, nausea or vomiting. In addition to the time to first
      request for supplemental oral analgesia, the following will be recorded: supplement analgesia
      dose requirements (number of acetaminophen/hydrocodone tablets) at 4, 8, 12, 18, and 24 h
      after the intrathecal injection.

      DNA collection: Peripheral blood will be collected in 2 5ml EDTA tubes (total 10ml). DNA will
      be prepared by non-phenolic methods using Puregene Blood Extraction Kit (Gentra, Minneapolis,
      MN) and tested for molecular weight on gel electrophoresis and purity quality by optical
      densitometry measure (ratio 260/280 nm).

      SNP genotyping: For identification of allelic distribution of the A118G SNP, 20-60 ng of DNA
      from individuals will be first amplified by PCR (on thermocycler apparatuses equipped with a
      96 well-microtiter plate block) using primers designed in the vicinity of the SNPs. The SNP
      will be then genotyped in amplified products by minisequencing (Pyrosequencing).

      Pyrosequencing: PCR using cDNA specific primers (spanning an intron in genomic DNA), in which
      the forward primer is labeled with 5' biotin is performed under standard conditions, and the
      product is analyzed by the Pyrosequencing method. Briefly, an internal primer is designed two
      nucleotides before the mutation site, so that the two mRNA populations could be assayed by
      quantifying the relative amounts of each allele present in the PCR product. DNA from normal
      and affected subjects are used as controls.

      PCR products are immobilized with Dynabeads (Dynal, Oslo, Norway) by a 15 min, 65 oC
      incubation in a buffer containing 10mM Tris-HCl, 2M NaCl, 1mM EDTA and 0.1% Tween 20. PCR
      products are then removed from solution using magnetic separation, denatured with NaOH 0.5 M
      and washed with 200mM Tris-Acetate, 50mM MgAc2. The remaining single stranded DNA is then
      hybridized with the internal 'sequencing' primer, by heating the mix to 80oC, and slowly
      cooling it to room temperature. Next enzyme and substrate mixes are automatically added to
      each well, and the reactions proceed at 28oC, by the sequential addition of single
      nucleotides at a predetermined order. Luciferase peak heights are proportional to the number
      of nucleotide incorporations, which has been shown to be very quantitative (5% error rate) in
      a number of experimental settings.

      Coded DNA samples will be stored in Dr. Blouin's laboratory. No further sequencing will be
      done unless subjects signed the consent form for further future studies.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of Intrathecal Fentanyl Analgesia</measure>
    <time_frame>Time (0-1440 minutes) to first analgesia request</time_frame>
    <description>Time from intrathecal drug administration to request for analgesia either in laboring women of after cesarean delivery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Intrathecal Analgesia Following Cesarean Delivery</measure>
    <time_frame>0 to 72 hours following cesarean delivery</time_frame>
    <description>Time until request for supplemental analgesia following intrathecal morphine/fentanyl for cesarean delivery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Pain Scale (0 to 100) at Analgesia Request Following Intrathecal Intervention</measure>
    <time_frame>VAS at analgesia request</time_frame>
    <description>Visual analog pain scale (0 to 100) at 1st request for supplemental analgesia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of Pruritus Following Fentanyl</measure>
    <time_frame>Labor analgesia</time_frame>
    <description>Severity of pruritus during labor analgesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With Pruritus at 24 Hours Post Morphine</measure>
    <time_frame>24 hours post cesarean delivery</time_frame>
    <description>Subjects reporting pruritus in the first 24 hours post cesarean delivery</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">293</enrollment>
  <condition>Labor Pain</condition>
  <condition>Post-cesarean Delivery</condition>
  <arm_group>
    <arm_group_label>Labor analgesia</arm_group_label>
    <description>Labor analgesia receiving fentanyl labor analgesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cesarean delivery analgesia</arm_group_label>
    <description>Cesarean delivery analgesia consisting of spinal fentanyl and morphine</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood Draw</intervention_name>
    <description>Blood for OPRM1 analysis</description>
    <arm_group_label>Labor analgesia</arm_group_label>
    <arm_group_label>Cesarean delivery analgesia</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood Samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Study 1: Laboring Women

          -  Nulliparous women in spontaneous labor or with spontaneous rupture of membranes

          -  Term pregnancy (≥ 37 weeks gestation)

          -  Vertex presentation

          -  Healthy, ASA PS 1-2

          -  Desire neuraxial labor analgesia.

        Study 2: Cesarean Delivery

          -  Nulliparous women undergoing elective primary Cesarean delivery (e.g., for breech
             presentation, macrosomia)

          -  Term pregnancy (≥ 37 weeks gestation)

          -  Healthy, ASA PS 1-2

          -  Desired spinal anesthesia.

        Exclusion Criteria:

        Study 1: Laboring Women

          -  Chronic or pregnancy induced disease

          -  Chronic opioid use

          -  History of substance abuse

          -  Systemic opioid analgesia before initiation of neuraxial labor analgesia

          -  Cervical dilation &lt; 2 cm or &gt; 5 cm of time of request for neuraxial analgesia

          -  Allergy to fentanyl

        Study 2: Cesarean delivery

          -  Chronic or pregnancy induced disease

          -  Chronic opioid use

          -  Previous abdominal or pelvic surgery

          -  Allergy to fentanyl, morphine, or bupivacaine

          -  BMI ≥ 40 kg/m2

          -  History of substance abuse

          -  Failed spinal anesthesia

          -  Requirement for systemic opioid supplementation during Cesarean delivery.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia A Wong, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Palmer SN, Giesecke NM, Body SC, Shernan SK, Fox AA, Collard CD. Pharmacogenetics of anesthetic and analgesic agents. Anesthesiology. 2005 Mar;102(3):663-71. Review.</citation>
    <PMID>15731608</PMID>
  </reference>
  <reference>
    <citation>Befort K, Filliol D, Decaillot FM, Gaveriaux-Ruff C, Hoehe MR, Kieffer BL. A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. J Biol Chem. 2001 Feb 2;276(5):3130-7. Epub 2000 Nov 6.</citation>
    <PMID>11067846</PMID>
  </reference>
  <reference>
    <citation>Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong JA, Leal SM, Tischfield JA, Kreek MJ, Yu L. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9608-13.</citation>
    <PMID>9689128</PMID>
  </reference>
  <reference>
    <citation>Grösch S, Niederberger E, Lötsch J, Skarke C, Geisslinger G. A rapid screening method for a single nucleotide polymorphism (SNP) in the human MOR gene. Br J Clin Pharmacol. 2001 Dec;52(6):711-4.</citation>
    <PMID>11736886</PMID>
  </reference>
  <reference>
    <citation>Höllt V. A polymorphism (A118G) in the mu-opioid receptor gene affects the response to morphine-6-glucuronide in humans. Pharmacogenetics. 2002 Jan;12(1):1-2.</citation>
    <PMID>11773858</PMID>
  </reference>
  <reference>
    <citation>Lötsch J, Skarke C, Grösch S, Darimont J, Schmidt H, Geisslinger G. The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics. 2002 Jan;12(1):3-9.</citation>
    <PMID>11773859</PMID>
  </reference>
  <reference>
    <citation>LaForge KS, Shick V, Spangler R, Proudnikov D, Yuferov V, Lysov Y, Mirzabekov A, Kreek MJ. Detection of single nucleotide polymorphisms of the human mu opioid receptor gene by hybridization or single nucleotide extension on custom oligonucleotide gelpad microchips: potential in studies of addiction. Am J Med Genet. 2000 Oct 9;96(5):604-15.</citation>
    <PMID>11054767</PMID>
  </reference>
  <reference>
    <citation>Wang D, Quillan JM, Winans K, Lucas JL, Sadée W. Single nucleotide polymorphisms in the human mu opioid receptor gene alter basal G protein coupling and calmodulin binding. J Biol Chem. 2001 Sep 14;276(37):34624-30. Epub 2001 Jul 16.</citation>
    <PMID>11457836</PMID>
  </reference>
  <reference>
    <citation>Town T, Abdullah L, Crawford F, Schinka J, Ordorica PI, Francis E, Hughes P, Duara R, Mullan M. Association of a functional mu-opioid receptor allele (+118A) with alcohol dependency. Am J Med Genet. 1999 Oct 15;88(5):458-61.</citation>
    <PMID>10490697</PMID>
  </reference>
  <reference>
    <citation>Shi J, Hui L, Xu Y, Wang F, Huang W, Hu G. Sequence variations in the mu-opioid receptor gene (OPRM1) associated with human addiction to heroin. Hum Mutat. 2002 Apr;19(4):459-60.</citation>
    <PMID>11933204</PMID>
  </reference>
  <reference>
    <citation>Schinka JA, Town T, Abdullah L, Crawford FC, Ordorica PI, Francis E, Hughes P, Graves AB, Mortimer JA, Mullan M. A functional polymorphism within the mu-opioid receptor gene and risk for abuse of alcohol and other substances. Mol Psychiatry. 2002;7(2):224-8.</citation>
    <PMID>11840318</PMID>
  </reference>
  <reference>
    <citation>Sander T, Gscheidel N, Wendel B, Samochowiec J, Smolka M, Rommelspacher H, Schmidt LG, Hoehe MR. Human mu-opioid receptor variation and alcohol dependence. Alcohol Clin Exp Res. 1998 Dec;22(9):2108-10.</citation>
    <PMID>9884158</PMID>
  </reference>
  <reference>
    <citation>Wong CA: Combined spinal-epidural labor analgesia. Techniques in Regional Anesthesia and Pain Management 2003; 7: 181-88</citation>
  </reference>
  <reference>
    <citation>Palmer CM, Cork RC, Hays R, Van Maren G, Alves D. The dose-response relation of intrathecal fentanyl for labor analgesia. Anesthesiology. 1998 Feb;88(2):355-61.</citation>
    <PMID>9477056</PMID>
  </reference>
  <reference>
    <citation>Nelson KE, Rauch T, Terebuh V, D'Angelo R. A comparison of intrathecal fentanyl and sufentanil for labor analgesia. Anesthesiology. 2002 May;96(5):1070-3.</citation>
    <PMID>11981144</PMID>
  </reference>
  <reference>
    <citation>Clarke VT, Smiley RM, Finster M. Uterine hyperactivity after intrathecal injection of fentanyl for analgesia during labor: a cause of fetal bradycardia? Anesthesiology. 1994 Oct;81(4):1083.</citation>
    <PMID>7943823</PMID>
  </reference>
  <reference>
    <citation>Landau R, Cahana A, Smiley RM, Antonarakis SE, Blouin JL. Genetic variability of mu-opioid receptor in an obstetric population. Anesthesiology. 2004 Apr;100(4):1030-3.</citation>
    <PMID>15087647</PMID>
  </reference>
  <reference>
    <citation>Palmer CM, Emerson S, Volgoropolous D, Alves D. Dose-response relationship of intrathecal morphine for postcesarean analgesia. Anesthesiology. 1999 Feb;90(2):437-44. Erratum in: Anesthesiology 1999 Apr;90(4):1241.</citation>
    <PMID>9952150</PMID>
  </reference>
  <reference>
    <citation>Ronaghi M, Uhlén M, Nyrén P. A sequencing method based on real-time pyrophosphate. Science. 1998 Jul 17;281(5375):363, 365.</citation>
    <PMID>9705713</PMID>
  </reference>
  <reference>
    <citation>Wasson J, Skolnick G, Love-Gregory L, Permutt MA. Assessing allele frequencies of single nucleotide polymorphisms in DNA pools by pyrosequencing technology. Biotechniques. 2002 May;32(5):1144-6, 1148, 1150 passim.</citation>
    <PMID>12019788</PMID>
  </reference>
  <reference>
    <citation>Neve B, Froguel P, Corset L, Vaillant E, Vatin V, Boutin P. Rapid SNP allele frequency determination in genomic DNA pools by pyrosequencing. Biotechniques. 2002 May;32(5):1138-42.</citation>
    <PMID>12019787</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 31, 2006</study_first_submitted>
  <study_first_submitted_qc>December 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2007</study_first_posted>
  <results_first_submitted>February 15, 2011</results_first_submitted>
  <results_first_submitted_qc>March 14, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 18, 2011</results_first_posted>
  <last_update_submitted>March 17, 2014</last_update_submitted>
  <last_update_submitted_qc>March 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Cynthia Wong</investigator_full_name>
    <investigator_title>Professor of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>µ-opioid receptor</keyword>
  <keyword>neuraxial labor analgesia</keyword>
  <keyword>pharmacogenetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Labor Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Laboring subject recruited from 10/2005 to 9/2006 Post cesarean delivery subjects recruited from 10/2005 to 5/2007</recruitment_details>
      <pre_assignment_details>Subjects were excluded from the labor analgesia group if they had received an opioid analgesic before initiation of intrathecal analgesia or if they received neuraxial analgesia before 2cm of cervical dilation.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Labor Analgesia OPRM1 c304A</title>
          <description>Parturients that received spinal fentanyl 15 micrograms and epidural fentanyl labor analgesia who were homozygous for OPRM1 c304</description>
        </group>
        <group group_id="P2">
          <title>Labor Analgesia OPRM1 c304A&gt;G</title>
          <description>Parturients receiving spinal fentanyl 15 micrograms and epidural fentanyl labor analgesia that were heterozygous or homozygous for OPRM1 c304A&gt;G</description>
        </group>
        <group group_id="P3">
          <title>Cesarean Delivery OPRM1 c304A</title>
          <description>Cesarean delivery subjects receiving morphine 150 micrograms with spinal bupivacaine 12mg and fentanyl 15 micrograms that were homozygous for OPRM1 c304A</description>
        </group>
        <group group_id="P4">
          <title>Cesarean Delivery OPRM1 c304A&gt;G</title>
          <description>Cesarean delivery subjects receiving morphine 150 micrograms with spinal bupivacaine 12mg and fentanyl 15 micrograms that were heterozygous for OPRM1 c304A&gt;G</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="78"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="78"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Labor Analgesia OPRM1 c304A</title>
          <description>Parturients that received spinal fentanyl 15 micrograms and epidural fentanyl labor analgesia who were homozygous for OPRM1 c304</description>
        </group>
        <group group_id="B2">
          <title>Labor Analgesia OPRM1 c304A&gt;G</title>
          <description>Parturients receiving spinal fentanyl 15 micrograms and epidural fentanyl labor analgesia that were heterozygous or homozygous for OPRM1 c304A&gt;G</description>
        </group>
        <group group_id="B3">
          <title>Cesarean Delivery OPRM1 c304A</title>
          <description>Cesarean delivery subjects receiving morphine 150 micrograms with spinal bupivacaine 12mg and fentanyl 15 micrograms that were homozygous for OPRM1 c304A</description>
        </group>
        <group group_id="B4">
          <title>Cesarean Delivery OPRM1 c304A&gt;G</title>
          <description>Cesarean delivery subjects receiving morphine 150 micrograms with spinal bupivacaine 12mg and fentanyl 15 micrograms that were heterozygous for OPRM1 c304A&gt;G</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="144"/>
            <count group_id="B2" value="46"/>
            <count group_id="B3" value="78"/>
            <count group_id="B4" value="25"/>
            <count group_id="B5" value="293"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" lower_limit="28" upper_limit="34"/>
                    <measurement group_id="B2" value="32" lower_limit="30" upper_limit="34"/>
                    <measurement group_id="B3" value="34" lower_limit="31" upper_limit="37"/>
                    <measurement group_id="B4" value="32" lower_limit="29" upper_limit="35"/>
                    <measurement group_id="B5" value="32" lower_limit="28" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Duration of Intrathecal Fentanyl Analgesia</title>
        <description>Time from intrathecal drug administration to request for analgesia either in laboring women of after cesarean delivery</description>
        <time_frame>Time (0-1440 minutes) to first analgesia request</time_frame>
        <population>Laboring parturients that received intrathecal fentanyl (25 micrograms) for initiation of labor analgesia were evaluated for this outcome per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Labor Analgesia OPRM1 c304A</title>
            <description>Parturients that received spinal fentanyl 15 micrograms and epidural fentanyl labor analgesia who were homozygous for OPRM1 c304</description>
          </group>
          <group group_id="O2">
            <title>Labor Analgesia OPRM1 c304A&gt;G</title>
            <description>Parturients receiving spinal fentanyl 15 micrograms and epidural fentanyl labor analgesia that were heterozygous or homozygous for OPRM1 c304A&gt;G</description>
          </group>
          <group group_id="O3">
            <title>Cesarean Delivery OPRM1 c304A</title>
            <description>Cesarean delivery subjects receiving morphine 150 micrograms with spinal bupivacaine 12mg and fentanyl 15 micrograms that were homozygous for OPRM1 c304A</description>
          </group>
          <group group_id="O4">
            <title>Cesarean Delivery OPRM1 c304A&gt;G</title>
            <description>Cesarean delivery subjects receiving morphine 150 micrograms with spinal bupivacaine 12mg and fentanyl 15 micrograms that were heterozygous for OPRM1 c304A&gt;G</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Intrathecal Fentanyl Analgesia</title>
          <description>Time from intrathecal drug administration to request for analgesia either in laboring women of after cesarean delivery</description>
          <population>Laboring parturients that received intrathecal fentanyl (25 micrograms) for initiation of labor analgesia were evaluated for this outcome per protocol.</population>
          <units>Minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70" lower_limit="62" upper_limit="78"/>
                    <measurement group_id="O2" value="63" lower_limit="50" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Log rank test</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.54</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Duration of Intrathecal Analgesia Following Cesarean Delivery</title>
        <description>Time until request for supplemental analgesia following intrathecal morphine/fentanyl for cesarean delivery</description>
        <time_frame>0 to 72 hours following cesarean delivery</time_frame>
        <population>Subjects that received fentanyl and morphine for postpartum analgesia after planned cesarean delivery were analyzed per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Labor Analgesia OPRM1 c304A</title>
            <description>Parturients that received spinal fentanyl 15 micrograms and epidural fentanyl labor analgesia who were homozygous for OPRM1 c304</description>
          </group>
          <group group_id="O2">
            <title>Labor Analgesia OPRM1 c304A&gt;G</title>
            <description>Parturients receiving spinal fentanyl 15 micrograms and epidural fentanyl labor analgesia that were heterozygous or homozygous for OPRM1 c304A&gt;G</description>
          </group>
          <group group_id="O3">
            <title>Cesarean Delivery OPRM1 c304A</title>
            <description>Cesarean delivery subjects receiving morphine 150 micrograms with spinal bupivacaine 12mg and fentanyl 15 micrograms that were homozygous for OPRM1 c304A</description>
          </group>
          <group group_id="O4">
            <title>Cesarean Delivery OPRM1 c304A&gt;G</title>
            <description>Cesarean delivery subjects receiving morphine 150 micrograms with spinal bupivacaine 12mg and fentanyl 15 micrograms that were heterozygous for OPRM1 c304A&gt;G</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Intrathecal Analgesia Following Cesarean Delivery</title>
          <description>Time until request for supplemental analgesia following intrathecal morphine/fentanyl for cesarean delivery</description>
          <population>Subjects that received fentanyl and morphine for postpartum analgesia after planned cesarean delivery were analyzed per protocol.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="78"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="26" lower_limit="0" upper_limit="47"/>
                    <measurement group_id="O4" value="40" lower_limit="0" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Pruritus Following Fentanyl</title>
        <description>Severity of pruritus during labor analgesia</description>
        <time_frame>Labor analgesia</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Labor Analgesia OPRM1 c304A</title>
            <description>Parturients that received spinal fentanyl 15 micrograms and epidural fentanyl labor analgesia who were homozygous for OPRM1 c304</description>
          </group>
          <group group_id="O2">
            <title>Labor Analgesia OPRM1 c304A&gt;G</title>
            <description>Parturients receiving spinal fentanyl 15 micrograms and epidural fentanyl labor analgesia that were heterozygous or homozygous for OPRM1 c304A&gt;G</description>
          </group>
          <group group_id="O3">
            <title>Cesarean Delivery OPRM1 c304A</title>
            <description>Cesarean delivery subjects receiving morphine 150 micrograms with spinal bupivacaine 12mg and fentanyl 15 micrograms that were homozygous for OPRM1 c304A</description>
          </group>
          <group group_id="O4">
            <title>Cesarean Delivery OPRM1 c304A&gt;G</title>
            <description>Cesarean delivery subjects receiving morphine 150 micrograms with spinal bupivacaine 12mg and fentanyl 15 micrograms that were heterozygous for OPRM1 c304A&gt;G</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Pruritus Following Fentanyl</title>
          <description>Severity of pruritus during labor analgesia</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With Pruritus at 24 Hours Post Morphine</title>
        <description>Subjects reporting pruritus in the first 24 hours post cesarean delivery</description>
        <time_frame>24 hours post cesarean delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Labor Analgesia OPRM1 c304A</title>
            <description>Parturients that received spinal fentanyl 15 micrograms and epidural fentanyl labor analgesia who were homozygous for OPRM1 c304</description>
          </group>
          <group group_id="O2">
            <title>Labor Analgesia OPRM1 c304A&gt;G</title>
            <description>Parturients receiving spinal fentanyl 15 micrograms and epidural fentanyl labor analgesia that were heterozygous or homozygous for OPRM1 c304A&gt;G</description>
          </group>
          <group group_id="O3">
            <title>Cesarean Delivery OPRM1 c304A</title>
            <description>Cesarean delivery subjects receiving morphine 150 micrograms with spinal bupivacaine 12mg and fentanyl 15 micrograms that were homozygous for OPRM1 c304A</description>
          </group>
          <group group_id="O4">
            <title>Cesarean Delivery OPRM1 c304A&gt;G</title>
            <description>Cesarean delivery subjects receiving morphine 150 micrograms with spinal bupivacaine 12mg and fentanyl 15 micrograms that were heterozygous for OPRM1 c304A&gt;G</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Pruritus at 24 Hours Post Morphine</title>
          <description>Subjects reporting pruritus in the first 24 hours post cesarean delivery</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="78"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Visual Analog Pain Scale (0 to 100) at Analgesia Request Following Intrathecal Intervention</title>
        <description>Visual analog pain scale (0 to 100) at 1st request for supplemental analgesia</description>
        <time_frame>VAS at analgesia request</time_frame>
        <population>Analysis population per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Labor Analgesia OPRM1 c304A</title>
            <description>Parturients that received spinal fentanyl 15 micrograms and epidural fentanyl labor analgesia who were homozygous for OPRM1 c304</description>
          </group>
          <group group_id="O2">
            <title>Labor Analgesia OPRM1 c304A&gt;G</title>
            <description>Parturients receiving spinal fentanyl 15 micrograms and epidural fentanyl labor analgesia that were heterozygous or homozygous for OPRM1 c304A&gt;G</description>
          </group>
          <group group_id="O3">
            <title>Cesarean Delivery OPRM1 c304A</title>
            <description>Cesarean delivery subjects receiving morphine 150 micrograms with spinal bupivacaine 12mg and fentanyl 15 micrograms that were homozygous for OPRM1 c304A</description>
          </group>
          <group group_id="O4">
            <title>Cesarean Delivery OPRM1 c304A&gt;G</title>
            <description>Cesarean delivery subjects receiving morphine 150 micrograms with spinal bupivacaine 12mg and fentanyl 15 micrograms that were heterozygous for OPRM1 c304A&gt;G</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Pain Scale (0 to 100) at Analgesia Request Following Intrathecal Intervention</title>
          <description>Visual analog pain scale (0 to 100) at 1st request for supplemental analgesia</description>
          <population>Analysis population per protocol.</population>
          <units>Units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="78"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" lower_limit="21" upper_limit="50"/>
                    <measurement group_id="O2" value="38" lower_limit="23" upper_limit="51"/>
                    <measurement group_id="O3" value="26" lower_limit="0" upper_limit="47"/>
                    <measurement group_id="O4" value="40" lower_limit="0" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.23</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.84</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Labor Analgesia OPRM1 c304A</title>
          <description>Parturients that received spinal fentanyl 15 micrograms and epidural fentanyl labor analgesia who were homozygous for OPRM1 c304</description>
        </group>
        <group group_id="E2">
          <title>Labor Analgesia OPRM1 c304A&gt;G</title>
          <description>Parturients receiving spinal fentanyl 15 micrograms and epidural fentanyl labor analgesia that were heterozygous or homozygous for OPRM1 c304A&gt;G</description>
        </group>
        <group group_id="E3">
          <title>Cesarean Delivery OPRM1 c304A</title>
          <description>Cesarean delivery subjects receiving morphine 150 micrograms with spinal bupivacaine 12mg and fentanyl 15 micrograms that were homozygous for OPRM1 c304A</description>
        </group>
        <group group_id="E4">
          <title>Cesarean Delivery OPRM1 c304A&gt;G</title>
          <description>Cesarean delivery subjects receiving morphine 150 micrograms with spinal bupivacaine 12mg and fentanyl 15 micrograms that were heterozygous for OPRM1 c304A&gt;G</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A limitation to the finding of this study was the relatively low number of OPRM1 heterozygous subjects.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Robert J. McCarthy</name_or_title>
      <organization>Northwestern University Feinberg School of Medicine</organization>
      <phone>3129269015</phone>
      <email>r-mccarthy@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

